We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals

131 hedge funds and large institutions have $956M invested in Aurinia Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 47 increasing their positions, 30 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 30

36% more call options, than puts

Call options by funds: $33.8M | Put options by funds: $24.9M

26% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 23

5% more funds holding

Funds holding: 125 → 131 (+6)

1.59% less ownership

Funds ownership: 53.86% → 52.27% (-1.6%)

18% less capital inflows, than outflows

Capital inflows: $115M | Capital outflows: $140M

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

Holders
131
Holders Change
+6
Holders Change %
+4.8%
% of All Funds
2.68%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.08%
New
29
Increased
47
Reduced
30
Closed
23
Calls
$33.8​M
Puts
$24.9​M
Net Calls
+$8.91​M
Net Calls Change
+$2.53​M

AUPH Hedge Fund Activity: Q2 2020 in Review

131 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q2 2020, worth a combined $956M — up 8.9% from $878M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new AUPH positions and 23 closed out — a net gain of 6 holders — while 47 added to existing stakes and 30 trimmed.

The largest buyer was Avidity Partners Management, adding an estimated $20.7M. The largest seller was Consonance Capital Management, cutting an estimated $36.6M.

  • 131 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q2 2020, up from 125 in Q1 2020.
  • Funds reported $956M of Aurinia Pharmaceuticals stock for Q2 2020, up 8.9% quarter-over-quarter.
  • 29 funds opened new Aurinia Pharmaceuticals positions in Q2 2020 and 23 closed out, a net change of +6 holders.
  • The largest Aurinia Pharmaceuticals buyer in Q2 2020 was Avidity Partners Management, an estimated $20.7M added.
  • The largest Aurinia Pharmaceuticals seller in Q2 2020 was Consonance Capital Management, an estimated $36.6M sold.

Based on aggregated 13F filings for Q2 2020.